|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400093446 |
|
最近更新日期: Date of Last Refreshed on: |
2024-12-05 09:18:24 |
|
注册时间: Date of Registration: |
2024-12-05 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
颈动脉 Crouse 斑块积分、CIMT 与冠状动脉病变相关性分析 |
|
Public title: |
Correlation Analysis of Carotid Crouse plaque score, CIMT and Coronary Artery Disease |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
《云南省“心脑同治”临床医学关键新技术研发》-子课题《基于心脏介入复合手术平台心脑同治临床关键技术及推广应用》-《颈动脉 Crouse 斑块积分、CIMT 与冠状动脉病变相关性分析》 |
|
Scientific title: |
Research and Development of Key New Technologies in Clinical Medicine of "Cardio-Brain Co-treatment" in Yunnan Province Subproject "Key Technologies and Promotion and Application of cardio-brain Co-treatment Based on cardiac Interventional Combined Surgery Platform" "Correlation Analysis of Carotid Crouse plaque score, CIMT and Coronary Artery Disease" |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘小永 |
研究负责人: |
孙林 |
|
Applicant: |
Liu Xiaoyong |
Study leader: |
Sun Lin |
|
申请注册联系人电话: Applicant telephone: |
+86 158 8781 8481 |
研究负责人电话:
Study leader's |
+86 138 8843 9860 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
792905435@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
sunlinkm@sina.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
云南省昆明市滇缅大道374号 |
研究负责人通讯地址: |
云南省昆明市滇缅大道374号 |
|
Applicant address: |
374 Yunnan-Burma Avenue, Kunming City, Yunnan Pr |
Study leader's address: |
374 Yunnan-Burma Avenue, Kunming City, Yunnan Pr |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
昆明医科大学第二附属医院 |
||
|
Applicant's institution: |
The Second Affiliated Hospital of Kunming Medical University |
||
|
研究负责人所在单位: |
昆明医科大学第二附属医院 |
||
|
Affiliation of the Leader: |
The Second Affiliated Hospital of Kunming Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
审-PJ-科-2024-72 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
昆明医科大学第二附属医院医学伦理委员 |
||
|
Name of the ethic committee: |
Committee member of Medical Ethics, the Second Affiliated Hospital of Kunming Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-03-18 00:00:00 | ||
|
伦理委员会联系人: |
钟巍 |
||
|
Contact Name of the ethic committee: |
Zhong Wei |
||
|
伦理委员会联系地址: |
云南省昆明市滇缅大道374号 |
||
|
Contact Address of the ethic committee: |
374 Yunnan-Burma Avenue, Kunming City, Yunnan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 871 6340 2346 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
昆明医科大学第二附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Affiliated Hospital of Kunming Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
云南省昆明市滇缅大道374号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
374 Yunnan-Burma Avenue, Kunming City, Yunnan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
重点研发计划 |
||||||||||||||||||||||
|
Source(s) of funding: |
Key research and development plan |
||||||||||||||||||||||
|
研究疾病: |
冠心病 |
||||||||||||||||||||||
|
Target disease: |
Coronary heart disease |
||||||||||||||||||||||
|
研究疾病代码: |
I25.103 |
||||||||||||||||||||||
|
Target disease code: |
I25.103 |
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
本研究通过超声测定颈动脉内斑块性质及颈动脉斑块Crouse积分、颈动脉内膜-中膜厚度,分析上述指标与CHD患者冠状动脉病变严重程度及病变斑块性质的相关性,旨在为临床治疗提供更多参考。 |
||||||||||||||||||||||
|
Objectives of Study: |
In this study, the properties of carotid plaque, carotid plaque Crouse score and carotid intium-media thickness were measured by ultrasound, and the correlation between the above indicators and the severity of coronary artery lesions and the properties of pathological plaques in CHD patients was analyzed, aiming to provide more references for clinical treatment. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
符合中华医学会心血管病学分会发布的《稳定性冠心病诊断与治疗指南》(2018)中的SAP诊断标准。 |
||||||||||||||||||||||
|
Inclusion criteria |
It meets the SAP diagnostic criteria in the Guidelines for Diagnosis and Treatment of Stable Coronary Heart Disease (2018) issued by the Chinese Society of Cardiology. |
||||||||||||||||||||||
|
排除标准: |
1、急性冠脉综合征; 2、严重感染性疾病; 3、血液系统疾病; 4、血肌酐>267μmol/L或存在肾衰竭; 5、患有免疫系统疾病; 6、合并有恶性肿瘤; 7、妊娠患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Acute coronary syndrome; 2. Serious infectious diseases; 3. Blood system diseases; 4. Serum creatinine > 267μmol/L or renal failure; 5. suffering from immune system diseases; 6. Combined with malignant tumor; 7. Pregnant patients. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-03-18 00:00:00至 To 2025-03-18 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-03-18 00:00:00 至 To 2025-03-18 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究公开发表后使用ResMan共享。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the research is publicly published, ResMan will be used for sharing. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
使用Excel、SPSS工具进行数据整理及分析 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Excel and SPSS were used to organize and analyze the data |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |